J&J selects MS&L to push Imodium in UK and abroad

Johnson and Johnson MSD has appointed Manning Selvage and Lee (MS&L) to work on UK and international PR for anti-diarrhoea drug Imodium.

Johnson and Johnson MSD has appointed Manning Selvage and Lee

(MS&L) to work on UK and international PR for anti-diarrhoea drug

Imodium.



The programme will target health professionals in a classic ’top down’

campaign. The aim is to challenge the preconception that diarrhoea is a

way of the body ridding itself of some kind of poison and therefore it

should be suffered in silence and not treated.



The PR campaign will present research which challenges this belief.



MS&L, whose healthcare clients include SmithKline Beecham and Glaxo

Wellcome, will also work on an international consumer campaign for

Imodium.



The consultancy will develop a core programme which will be presented to

franchise teams from across the globe, with the possibility of MS&L

affiliates winning more work. Charles Barker BSMG handles consumer PR

for Imodium in the UK.



Frances Beves, MS&L’s director of healthcare, said the agency was

excited to be working on an OTC product, after a shift towards ethical

work in the past few years.



MS&L was approached by Johnson and Johnson MSD to pitch for the account,

which it won after a three-way contest. Johnson and Johnson MSD is a

joint marketing initiative between Johnson and Johnson and drugs company

Merck Sharp and Dohme.



- MS&L has also been appointed to handle a business-to-business PR

campaign for drug-delivery company SkyPharma and to promote a growth

hormone therapy for Danish company Novo Nordisk.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.